John Hamill - Jan 30, 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SrVP/CFO/Prin. Fin&Acctg. Off
Signature
/s/ John P. Hamill
Stock symbol
APRE
Transactions as of
Jan 30, 2023
Transactions value $
$0
Form type
4
Date filed
1/30/2023, 04:21 PM
Previous filing
Jul 26, 2022
Next filing
Feb 27, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +270K $0.00 270K Jan 30, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Employee Stock Option (Right to Buy) Award $0 +540K $0.00 540K Jan 30, 2023 Common Stock 540K $0.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on January 30, 2023, and which will vest and be settled in common stock in three equal, annual installments beginning on January 30, 2024, January 30, 2025, and January 30, 2026, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on January 30, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.